Genetically engineered anti-CD19/CD20/CD22 CAR T-cells

CAR T-cell therapy targeting CD19, CD20, and CD22

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Genetically engineered anti-CD19/CD20/CD22 CAR T-cells, covering 2025-05-16 to 2025-05-16. Get the full timeline:

Most recent: Clinical Trial Update: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies [Phase 1]

See pricing